Completion of key step in IND transfer for upcoming Phase 2 breast cancer vaccine clinical trial
SAN JOSE, Calif., Nov. 5, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
Expands global intellectual property coverage in markets with high breast cancer incidence
New patent will provide IP protection of Breast Cancer Vaccine in China into 2040
SAN JOSE, Calif., Oct. 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology...
TW's Take: very exciting news. Looking forward to seeing the results, especially on the Keytruda arm, which would be the quickest pathway to an approved product.
Final Clinical Visit Marks Major Milestone in First-in-Human Evaluation of Breast Cancer Vaccine
Comprehensive Immune...
Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and Prevention
Comprehensive Results, Supported by U.S. Department of Defense Funding, to Inform FDA Discussions and Advance Phase 2 Development Plans
SAN JOSE, Calif., Sept. 22, 2025 /PRNewswire/ -- Anixa Biosciences,...
TW's Take: positive news from a program that is highly encouraging yet very slow to enroll. Looking forward to seeing some signs of efficacy in the future.
Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date
SAN JOSE,...
TW's Take: Anixa keeps moving the ball forward, albeit slowly as vaccine development takes a long time to come to fruition.
SAN JOSE, Calif., July 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the...
TW's Take: slow but steady progress from this program.
Fourth cohort dose is three million CAR positive cells; thirty times higher than the first cohort dose
SAN JOSE, Calif., June 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a...
TW's Take: the program continues to show great promise.
SAN JOSE, Calif., June 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair...
TW's Take: positive progress with meaningful catalysts coming in the future. The science is strong, the programs need to advance further for investor interest to really pick up.
SAN JOSE, Calif., May 19, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:...
TW's Take: slowly but surely, this program moves forward.
SAN JOSE, May 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Chief...
SAN JOSE, Calif., April 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has received a Notice of Allowance from the United States Patent...
Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach
SAN JOSE, Calif., April 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and...
SAN JOSE, Calif., March 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice...
TW's Take: enrollment continues to make slow and steady progress. Looking forward to seeing some efficacy data later this year.
SAN JOSE, Calif., Feb. 26, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment...
TW's Take: Anixa's CAR-T therapy continues to move forward slowly but with very interesting results. Potentially a blockbuster, just needs more patients treated to garner investor attention.
SAN JOSE, Calif., Feb. 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),...
Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies
SAN JOSE, Calif., Feb. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment...
TW's Take: this program continues to (slowly) show amazing potential. The third cohort could be what gets Wall Street interested.
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose
SAN JOSE, Calif., Nov....
TW's Take: positive data but need to see phase 2 results versus placebo before the stock will launch.
Data continues positive trend as additional patients are enrolled in 3 cohorts
Vaccine was safe and well tolerated by participants in...
TW's Take: I'm particularly looking forward to seeing the data from the Keytruda arm as that's what they intend to take forward immediately. Likely candidate for acquisition by MRK in the next year.
SAN JOSE, Calif., Oct. 28, 2024 /PRNewswire/ -- Anixa...
TW's Take: great early stage results from what could be a blockbuster therapy with the potential for efficacy across many indications.
Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from...
SAN JOSE, Calif., Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Suyasha Gupta as Senior Director of Clinical Development....
TW's Take: the safety profile of Anixa's treatment is obviously excellent if they are seeking approval for a second dose. Potential blockbuster treatment that is still in early stages but demonstrating huge potential so far.
Amendment will allow a...
TW's Take: This is a potentially big deal as results from this trial will start getting released to the market sometime in 2025. The combination with Keytruda makes a TON of sense and could provide a nice incentive for...
TW's Take: this novel therapy is gaining increasing recognition from the scientific community.
SAN JOSE, Calif., Sept. 18, 2024 -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that...
TW's Take: giving the opening keynote address is a big honor and demonstrates just how exciting ANIX's CAR-T program is. The therapy continues to fly beneath the radar screen but not for much longer.
SAN JOSE, Calif., Sept. 3, 2024 /PRNewswire/ -- Anixa...
TW's Take: nice industry recognition for what is looking, in the early stages, like a very interesting therapy with great potential for Anixa.
SAN JOSE, Calif., July 29, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused...
TW's Take: this is a very positive outcome for someone in the lowest dose cohort of this trial. While we need to see this across more patients, if this continues, the therapy could be on track for blockbuster status...
TW's Take: this is a display of confidence in the upcoming results from both programs. I expect to see positive CAR-T data in particular over the coming months.
SAN JOSE, Calif., July 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:...
TW's Take: enrollment is going much better now as it appears that the safety profile is excellent while there are initial signs of efficacy. Looking forward to seeing some clinical data around efficacy later this year, which, if positive,...
TW's Take: This therapy has the potential to be worth billions of dollars to Anixa and we could be getting results later this year...
Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid...
TW's Take: quite a positive step as partnering with the renowned Cleveland Clinic on additional vaccines speaks to how well the current trials are proceeding.
– Company currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines –
SAN JOSE,...
TW's Take: adding Dr. Juneja to the board should really help drive awareness of Anixa's programs.
SAN JOSE, Calif., April 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced...
TW's Take: Anixa's cancer vaccine continues to demonstrate excellent immune responses and is hopefully partnered off sometime in the next year at a significant premium to the current share price.
SAN JOSE, Calif., March 11, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),...
TW's Take: moving on to the second cohort is a big step forward as the initial cohort completes with zero significant adverse events, something that has plagued other company's solid tumor CAR-T therapies.
Dose escalation for fourth patient follows...
TW's Take: Anixa is slowly developing a portfolio of cancer vaccine assets and this is another step in that direction.
SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention...
TW's Take: excellent data from this novel vaccine program is setting the stage for Anixa to possibly change the whole landscape of cancer vaccine development. Very exciting news for breast cancer patients and investors in ANIX.
Antigen-specific T cell...
TW's Take: while early stage, this is based on the same technology as their breast cancer vaccine which is showing great results in phase 1.
SAN JOSE, Calif., Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology...
TW's Take: as this trial is now in its second cohort, good to see it getting some industry recognition.
Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial
SAN JOSE, Calif., Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or...
SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory...
TW's Take: Great news as this exciting therapy advances towards larger doses and, hopefully, efficacy.
- With no dose-limiting toxicities observed, treatment of second dose cohort to begin
SAN JOSE, Calif., Oct. 13, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX),...
TW's Take: early stage but an exciting program based on work from the inventor of their breast cancer vaccine, which is going very well.
SAN JOSE, Calif., Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company...
TW's Take: this is a very strong group of individuals. Hopefully the establishment of this board leads to a meaningful partnership on one or more of their programs in the not too distant future.
SAN JOSE, Calif., Sept. 19, 2023 /PRNewswire/ -- Anixa...
TW's Take: enrollment is finally picking up and the therapy has shown an excellent safety profile and some moderate efficacy at the initial, sub-therapeutic levels. Looking forward to getting data later this year and hopeful that enrollment continues to...
TW's Take: more scientific validation for this unique therapy provides further evidence of a potentially blockbuster solid-tumor cancer platform.
SAN JOSE, Calif., Aug. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and...
TW's Take: my thinking behind this "news story" is that management is frustrated by the lack of value being assigned to the company in light of the outstanding data from this program.
SAN JOSE, CA / ACCESSWIRE / August 10,...
TW's Take: this trial will have meaningful results in December which could be the closest game-changing event for Anixa. Very exciting opportunity that the market is dramatically under-appreciating.
SAN JOSE, Calif., Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:...
TW's Take: this program has great potential and is overlooked by the market, but is very early stage so not really impactful to today's stock price.
SAN JOSE, Calif., July 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a...
TW's Take: the company continues to build their patent portfolio while we await more data from the program. Hopefully we will learn more in the coming weeks.
Technology currently being evaluated for the treatment of ovarian cancer in Phase...
TW's Take: nice to see this program gaining some momentum. Due to changes in their recruitment process, expect to see enrollment accelerate and results from patients should start coming out fairly consistently going forward. Success in a solid tumor...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
Yesterday Anixa (ANIX) traded down 25% on the back of a data release from...
TW's Take: very positive data from this program. Market continues to under-appreciate this company and its data.
SAN JOSE, Calif. -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic...
Tailwinds Research (TW) – Your presentation at AACR looked impressive, but how should investors interpret the data?
Dr. Amit Kumar (AK) – In this first phase of the trial, we wanted to confirm that it was safe, that we could...
TW's Take: looking forward to seeing the results of this breakthrough vaccine which should be a major catalyst for Anixa.
SAN JOSE, Calif., March 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
TW's Take: all systems go for the vaccine as we await key data in April that should be the catalyst for shares of ANIX.
SAN JOSE, Calif., Feb. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the...
TW's Take: an impressive board of individuals who likely believe in the future success of this vaccine if they are lending their name to the program.
SAN JOSE, Calif., Feb. 21, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on...
TW's Take: nice to see that phase 1a is on track to present data in Q2 of next year. This will be a significant milestone for the stock and potentially for women everywhere.
SAN JOSE, Calif., Dec. 8, 2022 /PRNewswire/ -- Anixa Biosciences,...
TW's Take: this trial continues to run ahead of expectations and increased awareness will position ANIX for a strong move into data in 2023.
SAN JOSE, Calif., Nov. 8, 2022 -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment...
TW's Take: the scientific community is getting increasingly excited about Anixa's CAR-T treatment as demonstrated by its upcoming presentations at important conferences.
SAN JOSE, Calif., Oct. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention...
TW's Take: Anixa's Breast Cancer Vaccine program moving into phase 1b this quickly is definitive proof that they have seen excellent results so far. Now they move into healthy volunteers who are, due to genetically high risk of TNBC,...
TW's Take: with the first patient showing stable disease and great safety data, this program is certainly off to a great start. Potential blockbuster opportunity. We'll know in the next few patients (meaning in the next six months!) just...
TW's Take: we are very excited to learn more about this program and this event could be a very nice catalyst for the stock.
SAN JOSE, Calif., Sept. 12, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment...
TW Research (TW) - First off, congrats on dosing your first patient in your Ovarian cancer trial. It took a lot longer than expected but now you’re in humans with a solid tumor immunotherapy. Looking at this trial, what...
TW's Take: very exciting news as Anixa now has a second potentially blockbuster program in the clinic. CER-T results are expected to be released in 2022, providing another large catalyst in the second half of the year. I continue...
TW's Take: Anixa continues to move this program forward. Expect compelling data from the ongoing phase 1 trial sometime late in 2022.
SAN JOSE, Calif., July 21, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and...
TW's Take: on the back of their breast cancer vaccine trial, which is seeing excellent early results, Anixa's ovarian cancer vaccine could be their third clinical-stage compound sometime around the end of next year...if their covid therapeutic doesn't beat...
This past weekend I spent mountain biking in Downieville. Our group gets shuttled up to the top of the mountain and then careen down as fast as we dare. It can be a thrilling ride with potential disaster looming...
This week I'm writing my newsletter on Thursday as I'm heading out to California this afternoon. The upcoming weekend will be spent in Downieville, a former mining town that is now a mountain biking mecca. It should be a...
The saying about insider stock transactions goes like this, "there are many reasons for insiders to sell but only one reason for them to buy." Like most stock market aphorisms, history shows this holds far more than a grain...
Last week was the second week in a row where the TW portfolio was basically unchanged. A sign that markets are calming down? Actually, nothing could be further from the truth. The volatility in stocks is picking up daily...
TW's Take: quite positive that this trial is getting attention from ASCO, the preeminent cancer meeting. We believe Cleveland Clinic is likely to also present some patient data along with the trial design.
SAN JOSE, Calif., April 28, 2022 /PRNewswire/ -- Anixa...
This past week in Charlottesville, The Boar's Head Women's Open took place. This is an annual tennis tournament featuring 32 professional tennis players, most of whom are ranked in the top 250 in the world. Several past winners of...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
On Wednesday we had a Zoom call with Dr. Amit Kumar, the CEO of...
TW's Take: nice to see Moffitt getting more aggressive in taking this novel solid tumor CAR-T treatment out to the medical community. Success here is greatly discounted in the shares of Anixa.
SAN JOSE, Calif., April 6, 2022 /PRNewswire/ -- Anixa Biosciences, Inc....
TW's Take: Finally!!! Great news that this trial has been given the go-ahead from the FDA. Possibly revolutionary for treatment of solid tumors as, if successful, it would be the first of its kind. We could hear preliminary results...
Another week in the market, another leg down. Some pundits are saying we are now entering a bear market. Those of us who invest in micro-caps know that we've been mauled by the bear for over a year now....
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~
I touched base with Anixa (ANIX)'s CEO Dr. Amit Kumar yesterday. Here's a brief...
TW's Take: Covid is here to stay and Anixa is showing excellent early stage results in a program that has cost very little to get to this point. Hoping to see them partner the program sometime later this year.
SAN...
Knock me over with a feather but there's finally been some movement in the ParkerVision (PRKR) vs. Qualcomm (QCOM) trial in Orlando. This is very exciting for the Company as they have been waiting many years for their day...
TW's Take: this program continues to make solid, albeit early-stage, progress. Covid isn't going away and Anixa has an opportunity here long-term.
SAN JOSE, Calif. and STUTTGART, Germany, Dec. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused...
My constant refrain for most of 2021 has been that I don't like the market but love the stocks in my portfolio. I can honestly say that across the board I've built a collection of exciting companies that are...
Well, that didn't last long, did it? On Tuesday and Wednesday we saw what looked like a great reversal for biotech. The XBI opened dramatically lower on Tuesday then reversed into a nice gain. With a similar move on...
Intelligent investing can truly be boiled down to the understanding of risk and reward. In order to properly assess the potential risks of an investment, and to understand the potential rewards, an investor has to perform extensive due diligence....
TW's Take: exciting news for Anixa and for women as the first ever vaccine for breast cancer trial has launched. We believe that this phase 1 trial's design has a high likelihood of success in their biomarker endpoints and...
Rode the train up to DC from Charlottesville on Friday night and, let me tell you, despite all the years and money thrown at Amtrak, they still manage to make trips a lot longer than they should be.
On Friday,...
In a slow week for news from our universe of companies, the biggest news was from TFF Pharma (TFFP) which announced pre-clinical success of their monoclonal antibody (mAb) Covid-19 therapeutic. In what I believe is a must-read piece for...
TW's Take: patent protection in China is an unexpected surprise. We are looking forward to seeing the company begin both their human trials during Q4.
SAN JOSE, Calif., Oct. 6, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused...
September to remember? I had such high hopes. Sadly, it turned out to be a very forgettable month and I'm happy to have it behind me.
I was concerned about the market going into the historically weakest month of the...
TW's Take: a positive that this patent helps broaden coverage of the technology in other cancers besides ovarian. If this CAR-T therapy proves effective, will be a game-changing event for Anixa.
SAN JOSE, Calif., Oct. 1, 2021 /PRNewswire/ -- Anixa Biosciences,...
The markets had another downward-trending week since the last newsletter. However, the overall tone of the market felt better from a micro-cap investing standpoint and my bi-polar attitude (loving my stocks, not liking the market) feels rather appropriate. Despite...
TW's Take: as this promising treatment moves into the clinic later this year, there will be increased attention paid to Anixa and their partner, Moffitt. If this treatment is successful, it will be the first solid-tumor CAR-T that has...
TW's Take: Nice to see Dr. Kumar begin to build out the team around himself. Anixa is about to get very busy with two programs entering the clinic in the next several months.
SAN JOSE, Calif., Sept. 7, 2021 /PRNewswire/...
TW's Take: great news that will allow this exciting program to start human trials sometime in the next 6 months (hopefully by year-end).
SAN JOSE, Calif., Aug. 30, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on...
TW's Take: while this program is still in the early stages of development, this demonstrates they are heading in the right direction with their efforts. Bigger news will be dosing of first patient in the breast cancer vaccine trial,...
TW's Take: an exciting early stage program with a world-class partner. The risk/reward of Anixa is very skewed to the positive at current valuations.
SAN JOSE, Calif., Aug. 18, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused...